UNSPSC 51334303: Flupentixol

This classification denotes a serotonin antagonist and dopamine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FA0UYH6QUO. European Medicines Agency schedules Flupentixol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07726MIG. Flupentixol generally arises in the molecular formula C23H25F3N2OS. The term FLUPENTIXOL is an International Non-Proprietary Name or INN. FLUPENTIXOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule flupentixol under HS 29349990 and SITC 51579. As of Q4 2014, FLUPENTIXOL remains the US FDA Preferred Term for this commodity. Flupentixol bears US NLM identifiers UMLS ID C0016367 and NCI Concept Code C73315. SMILES: S1C2C(/C(=C/CCN3CCN(CC3)CCO)C3C1CCCC3)CC(CC2)C(F)(F)F.

UNSPSC 51334303 Flupentixol, a Commodity code, does not align with the recent state and local procurement activity posted under it. The three most recent opportunities—a Seminole County naloxone and drug deactivation systems bid, a Texas HHS direct-to-manufacturer prescription RFI, and a Minnesota cooperative purchasing RFP for generic multi-source pharmaceuticals and OTC products—target pharmaceutical procurement, supply chain management, and community health initiatives broadly, but do not specifically solicit flupentixol, an antipsychotic medication. The mismatch suggests either miscoding of opportunities by issuing bodies or a code designation that does not reflect current demand signals in state and local government pharmaceutical purchasing.

The recent opportunities reveal activity across state health and human services departments, county public health agencies, and cooperative purchasing alliances spanning Florida, Texas, Minnesota, and Oregon. The Tennessee-based Seminole County IFB (S1070000015802, due July 26, 2026) seeks 1,900 units of naloxone annually with quarterly deliveries; the Texas Health and Human Services Commission RFI (HHS0017013, April 2026 response deadline) explores direct-to-manufacturer pharmacy contracting models; and the Minnesota MMCAP RFP (due March 26, 2026) establishes multi-state contracts for generic pharmaceuticals through authorized wholesalers including Cencora and Cardinal Health, with awards effective July 1, 2026. Given the code's lack of direct relevance to recent solicitations, the commodity shows little current activity targeting flupentixol specifically and warrants reclassification review with issuing bodies or further market research to identify whether demand for this antipsychotic exists in state and local mental health or correctional health programs.